Medpage Today on MSN1d
Risk-Reducing Surgery May Benefit BRCA Carriers With Early-Onset Breast CancerAmong more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
New research shows that young breast cancer patients with high-risk genes may be able to prevent their cancer from returning ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback